Minerva Neurosciences, Inc.

NERV

Healthcare|Biotechnology|US

$2.42

+0.12 (+5.22%)

DCF Value

$1.98

Cash / Share

$1.56

Clinical Trials (7)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT07565428 Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications	Negative Symptoms of Schizophrenia	P3	Recruiting	380	RCT, Double-blind	Roluperidone, risperidone, aripiprazole, olanzapine, Placebo
NCT03397134 Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia	Negative Symptoms of Schizophrenia	P3	Completed	515	RCT, Double-blind	Placebo Oral Tablet, Roluperidone 32 mg, Roluperidone 64 mg
NCT03446846 A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder	Major Depressive Disorder	P2	Completed	360	RCT, Double-blind	MIN-117 5.0 mg, MIN-117 2.5 mg, Placebo
NCT06107803 A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia	Negative Symptoms in Schizophrenia	P1	Completed	17	Open-label	Roluperidone 64 mg, Olanzapine 10 MG
NCT03038646 A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects	Healthy Subjects	P1	Completed	14	RCT, Open-label	MIN-101
NCT02232529 Pharmacokinetic Study of MIN-101 in Healthy Subjects	Schizophrenia	P1	Completed	32	RCT	MIN-101, Placebo
NCT03072056 A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers	Healthy Subjects	P1	Completed	23	Open-label	MIN-101